Sonia M Najjar Selected Research

Hyperinsulinism (Hyperinsulinemia)

11/2020	Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis.
1/2019	Hepatic Insulin Clearance: Mechanism and Physiology.
1/2019	Hyperinsulinemia drives hepatic insulin resistance in male mice with liver-specific Ceacam1 deletion independently of lipolysis.
1/2018	Liver-specific rescuing of CEACAM1 reverses endothelial and cardiovascular abnormalities in male mice with null deletion of Ceacam1 gene.
1/2018	Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis.
1/2017	Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease.
1/2017	Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism.
11/2015	High-fat diet amplifies renal renin angiotensin system expression, blood pressure elevation, and renal dysfunction caused by Ceacam1 null deletion.
9/2015	Differential effects of prenatal stress on metabolic programming in diet-induced obese and dietary-resistant rats.
8/2015	Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sonia M Najjar Research Topics

Disease

42	Insulin Resistance 04/2022 - 03/2002
20	Hyperinsulinism (Hyperinsulinemia) 11/2020 - 03/2002
15	Obesity 10/2018 - 09/2006
12	Abdominal Obesity 01/2021 - 10/2004
8	Inflammation (Inflammations) 04/2022 - 01/2014
8	Fatty Liver 01/2019 - 08/2013
7	Non-alcoholic Fatty Liver Disease 01/2021 - 12/2008
6	Fibrosis (Cirrhosis) 04/2022 - 12/2008
5	Glucose Intolerance 12/2021 - 09/2006
5	Hyperphagia (Overeating) 01/2019 - 08/2010
5	Body Weight (Weight, Body) 01/2018 - 12/2012
4	Neoplasms (Cancer) 01/2020 - 01/2002
4	Type 2 Diabetes Mellitus (MODY) 11/2016 - 08/2002
4	Hypertension (High Blood Pressure) 03/2012 - 08/2002
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2015 - 10/2004
2	Atherosclerosis 04/2022 - 11/2020
2	Hypercholesterolemia 04/2022 - 11/2020
2	Liver Diseases (Liver Disease) 01/2021 - 10/2018
2	Dyslipidemias (Dyslipidemia) 11/2020 - 11/2016
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 05/2004
2	Alcoholic Fatty Liver 10/2018 - 01/2014
2	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 04/2016
2	Thrombosis (Thrombus) 03/2016 - 10/2014
2	Hyperglycemia 01/2015 - 07/2010
2	Glucocorticoid Receptor Deficiency 09/2010 - 07/2010
1	Atherosclerotic Plaque (Atheroma) 04/2022
1	Chronic Hepatitis B 01/2021
1	Leukemia 01/2020
1	Cardiovascular Abnormalities 01/2018
1	Metabolic Diseases (Metabolic Disease) 01/2017
1	Albuminuria 11/2015
1	Birth Weight (Birth Weights) 09/2015
1	Genetic Predisposition to Disease (Genetic Predisposition) 09/2015

Drug/Important Bio-Agent (IBA)

38	Insulin (Novolin)FDA Link 04/2022 - 03/2002
34	CEACAM1 ProteinIBA 04/2022 - 01/2002
10	LipidsIBA 01/2018 - 10/2009
6	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2019 - 09/2006
5	Glucose (Dextrose)FDA LinkGeneric 11/2018 - 09/2006
4	Carcinoembryonic AntigenIBA 01/2021 - 05/2010
4	Cell Adhesion MoleculesIBA 01/2020 - 05/2010
3	Nonesterified Fatty Acids (NEFA)IBA 12/2021 - 10/2004
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 08/2013
3	LeptinIBA 01/2021 - 05/2016
3	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2020 - 08/2002
3	CD66 antigensIBA 09/2017 - 10/2014
3	Triglycerides (Triacylglycerol)IBA 08/2015 - 09/2006
3	Proteins (Proteins, Gene)FDA Link 12/2008 - 01/2002
2	AdipokinesIBA 01/2021 - 10/2009
2	Insulin ReceptorIBA 11/2020 - 07/2004
2	Phosphotransferases (Kinase)IBA 11/2020 - 01/2020
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 04/2016
2	Exenatide (Byetta)FDA Link 01/2018 - 01/2017
2	Oxygen (Dioxygen)IBA 03/2009 - 07/2008
1	Coloring Agents (Dyes)IBA 04/2022
1	Nicotinamide MononucleotideIBA 12/2021
1	NAD (NADH)IBA 12/2021
1	AdiponectinIBA 01/2021
1	Cell Adhesion Molecule-1IBA 01/2021
1	Transferrin (beta 2 Transferrin)IBA 01/2021
1	Niacin (Nicotinic Acid)FDA LinkGeneric 01/2021
1	Hormones (Hormone)IBA 01/2021
1	Nitric Oxide Synthase (NO Synthase)IBA 11/2020
1	AlbuminsIBA 11/2020
1	Endothelin-1 (Endothelin 1)IBA 11/2020
1	interferon regulatory factor-8 (interferon consensus sequence binding protein)IBA 01/2020
1	Insulysin (Insulin-Degrading Enzyme)IBA 11/2018
1	Indicators and Reagents (Reagents)IBA 10/2018
1	Retinoid X Receptor alphaIBA 01/2018
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2017
1	Fenofibrate (CiL)FDA LinkGeneric 11/2016
1	Pharmaceutical PreparationsIBA 11/2016
1	Rosiglitazone (Avandia)FDA Link 10/2016
1	pirinixic acidIBA 04/2016
1	Messenger RNA (mRNA)IBA 04/2016
1	Blood Glucose (Blood Sugar)IBA 09/2015
1	C-PeptideIBA 09/2015
1	Small Interfering RNA (siRNA)IBA 03/2015
1	Chlorogenic AcidIBA 01/2015
1	Dietary Fats (Dietary Fat)IBA 01/2015
1	ChromiumIBA 01/2015
1	Antisense OligonucleotidesIBA 07/2014
1	acetovanillone (apocynin)IBA 07/2014
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 07/2014
1	Acetylcysteine (Siran)FDA LinkGeneric 07/2014
1	Serine (L-Serine)FDA Link 07/2014
1	AntioxidantsIBA 07/2014
1	NADPH Oxidases (NAD(P)H oxidase)IBA 07/2014
1	Estrogens (Estrogen)FDA Link 04/2014
1	Prorenin ReceptorIBA 08/2013
1	Nicotine FDA Link 12/2012
1	SaltsIBA 03/2012
1	tissue-factor-pathway inhibitor 2 (PP5)IBA 12/2011
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2011
1	Estrogen ReceptorsIBA 08/2011
1	glucocorticoid receptor betaIBA 09/2010

Therapy/Procedure

2	Intraperitoneal Injections 01/2019 - 01/2018
1	Therapeutics 01/2021
1	Liver Transplantation 03/2016
1	Injections 12/2012
1	Caloric Restriction 11/2010